These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 15956983

  • 1. Coexpression of CD40L and CD70 by semiallogenic tumor cells induces anti-tumor immunity.
    Cormary C, Hiver E, Mariamé B, Favre G, Tilkin-Mariamé AF.
    Cancer Gene Ther; 2005 Dec; 12(12):963-72. PubMed ID: 15956983
    [Abstract] [Full Text] [Related]

  • 2. Induction of T-cell antitumor immunity and protection against tumor growth by secretion of soluble human CD70 molecules.
    Cormary C, Gonzalez R, Faye JC, Favre G, Tilkin-Mariamé AF.
    Cancer Gene Ther; 2004 Jul; 11(7):497-507. PubMed ID: 15153937
    [Abstract] [Full Text] [Related]

  • 3. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status.
    Douin-Echinard V, Bornes S, Rochaix P, Tilkin AF, Peron JM, Bonnet J, Favre G, Couderc B.
    Cancer Gene Ther; 2000 Dec; 7(12):1543-56. PubMed ID: 11228533
    [Abstract] [Full Text] [Related]

  • 4. In vivo induction of antitumor immunity and protection against tumor growth by injection of CD154-expressing tumor cells.
    Grangeon C, Cormary C, Douin-Echinard V, Favre G, Couderc B, Tilkin-Mariamé AF.
    Cancer Gene Ther; 2002 Mar; 9(3):282-8. PubMed ID: 11896445
    [Abstract] [Full Text] [Related]

  • 5. Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells.
    Couderc B, Zitvogel L, Douin-Echinard V, Djennane L, Tahara H, Favre G, Lotze MT, Robbins PD.
    Cancer Gene Ther; 1998 Mar; 5(3):163-75. PubMed ID: 9622100
    [Abstract] [Full Text] [Related]

  • 6. Immuno-gene therapy with adenoviruses expressing fms-like tyrosine kinase 3 ligand and CD40 ligand for mouse hepatoma cells in vivo.
    Yanagi K, Nagayama Y, Nakao K, Saeki A, Matsumoto K, Ichikawa T, Ishikawa H, Hamasaki K, Ishii N, Eguchi K.
    Int J Oncol; 2003 Feb; 22(2):345-51. PubMed ID: 12527933
    [Abstract] [Full Text] [Related]

  • 7. Complete rejection of a T-cell lymphoma due to synergism of T-cell receptor costimulatory molecules, CD80, CD40L, and CD40.
    Ruybal P, Gravisaco MJ, Barcala V, Escalada A, Di Sciullo P, Waldner C, Mongini C.
    Vaccine; 2008 Jan 30; 26(5):697-705. PubMed ID: 18155328
    [Abstract] [Full Text] [Related]

  • 8. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection.
    Kelly JM, Darcy PK, Markby JL, Godfrey DI, Takeda K, Yagita H, Smyth MJ.
    Nat Immunol; 2002 Jan 30; 3(1):83-90. PubMed ID: 11743585
    [Abstract] [Full Text] [Related]

  • 9. Herpes simplex virus type-1 amplicon vectors for vaccine generation in acute lymphoblastic leukemia.
    Zibert A, Thomassen A, Müller L, Nguyen L, Glouchkova L, Fraefel C, Roskrow M, Meisel R, Dilloo D.
    Gene Ther; 2005 Dec 30; 12(23):1707-17. PubMed ID: 16034459
    [Abstract] [Full Text] [Related]

  • 10. Expression of costimulatory molecules on human retinoblastoma cells Y-79: functional expression of CD40 and B7H1.
    Usui Y, Okunuki Y, Hattori T, Takeuchi M, Kezuka T, Goto H, Usui M.
    Invest Ophthalmol Vis Sci; 2006 Oct 30; 47(10):4607-13. PubMed ID: 17003458
    [Abstract] [Full Text] [Related]

  • 11. Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma.
    Liu Y, Xia D, Li F, Zheng C, Xiang J.
    Cancer Gene Ther; 2005 Feb 30; 12(2):122-32. PubMed ID: 15565183
    [Abstract] [Full Text] [Related]

  • 12. CD27-CD27 ligand/CD70 interactions enhance alloantigen-induced proliferation and cytolytic activity in CD8+ T lymphocytes.
    Brown GR, Meek K, Nishioka Y, Thiele DL.
    J Immunol; 1995 Apr 15; 154(8):3686-95. PubMed ID: 7706711
    [Abstract] [Full Text] [Related]

  • 13. Stable expression of chimeric anti-CD3 receptors on mammalian cells for stimulation of antitumor immunity.
    Liao KW, Chen BM, Liu TB, Tzou SC, Lin YM, Lin KF, Su CI, Roffler SR.
    Cancer Gene Ther; 2003 Oct 15; 10(10):779-90. PubMed ID: 14502231
    [Abstract] [Full Text] [Related]

  • 14. Dendritic and tumor cell fusions transduced with adenovirus encoding CD40L eradicate B-cell lymphoma and induce a Th17-type response.
    Alvarez E, Moga E, Barquinero J, Sierra J, Briones J.
    Gene Ther; 2010 Apr 15; 17(4):469-77. PubMed ID: 20010627
    [Abstract] [Full Text] [Related]

  • 15. A GM-CSF/CD40L producing cell augments anti-tumor T cell responses.
    Dessureault S, Alsarraj M, McCarthy S, Hunter T, Noyes D, Lee D, Harkins J, Seigne J, Jennings R, Antonia SJ.
    J Surg Res; 2005 May 15; 125(2):173-81. PubMed ID: 15854671
    [Abstract] [Full Text] [Related]

  • 16. Glioblastomas induce T-lymphocyte death by two distinct pathways involving gangliosides and CD70.
    Chahlavi A, Rayman P, Richmond AL, Biswas K, Zhang R, Vogelbaum M, Tannenbaum C, Barnett G, Finke JH.
    Cancer Res; 2005 Jun 15; 65(12):5428-38. PubMed ID: 15958592
    [Abstract] [Full Text] [Related]

  • 17. Naked RNA vaccine controls tumors with down-regulated MHC class I expression through NK cells and perforin-dependent pathways.
    Cheng WF, Hung CF, Lee CN, Su YN, Chang MC, He L, Wu TC, Chen CA, Hsieh CY.
    Eur J Immunol; 2004 Jul 15; 34(7):1892-900. PubMed ID: 15214037
    [Abstract] [Full Text] [Related]

  • 18. Comparative analysis of antitumor activity of CD40L, RANKL, and 4-1BBL in vivo following intratumoral administration of viral vectors or transduced dendritic cells.
    Yurkovetsky ZR, Shurin GV, Barry DA, Schuh AC, Shurin MR, Robbins PD.
    J Gene Med; 2006 Feb 15; 8(2):129-37. PubMed ID: 16288496
    [Abstract] [Full Text] [Related]

  • 19. In vivo antitumor effect of CD40L-transduced tumor cells as a vaccine for B-cell lymphoma.
    Briones J, Timmerman J, Levy R.
    Cancer Res; 2002 Jun 01; 62(11):3195-9. PubMed ID: 12036933
    [Abstract] [Full Text] [Related]

  • 20. Allogeneic MHC gene transfer enhances antitumor activity of allogeneic hematopoietic stem cell transplantation without exacerbating graft-versus-host disease.
    Ohashi M, Kobayashi A, Hara H, Miura Y, Yoshida K, Kushida M, Ikarashi Y, Mandai M, Kitajima M, Yoshida T, Aoki K.
    Clin Cancer Res; 2006 Apr 01; 12(7 Pt 1):2208-15. PubMed ID: 16609036
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.